Beam Therapeutics Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Beam Therapeutics stock.
View analyst ratings for Beam Therapeutics or view top-rated stocks.

Wall Street analysts have given Beam Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Beam Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Beam Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Beam Therapeutics.

Beam Therapeutics Inc. (NASDAQ:BEAM) issued its quarterly earnings data on Monday, May, 10th. The company reported ($3.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $2.61. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $6 million. Beam Therapeutics had a negative net margin of 1,523,724.75% and a negative trailing twelve-month return on equity of 113.20%.
View Beam Therapeutics' earnings history.

Beam Therapeutics' stock was trading at $21.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BEAM stock has increased by 300.0% and is now trading at $85.00.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued 1-year target prices for Beam Therapeutics' shares. Their forecasts range from $33.00 to $145.00. On average, they expect Beam Therapeutics' share price to reach $94.17 in the next twelve months. This suggests a possible upside of 10.8% from the stock's current price.
View analysts' price targets for Beam Therapeutics or view top-rated stocks among Wall Street analysts.

1 employees have rated Beam Therapeutics CEO on Glassdoor.com. has an approval rating of 100% among Beam Therapeutics' employees. This puts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Beam Therapeutics include Bio-Techne (TECH), Novozymes A/S (NVZMY), argenx (ARGX), Novavax (NVAX), Repligen (RGEN), QIAGEN (QGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Fate Therapeutics (FATE), Exelixis (EXEL), Vir Biotechnology (VIR), Halozyme Therapeutics (HALO) and Adaptive Biotechnologies (ADPT).
View all of BEAM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Square (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

(BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM."

Beam Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (7.64%), BlackRock Inc. (4.94%), Redmile Group LLC (4.05%), MWG Management Limited (3.78%), Hillhouse Capital Advisors LTD. (3.31%) and Goldman Sachs Group Inc. (1.17%).
View institutional ownership trends for Beam Therapeutics.

BEAM stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Hillhouse Capital Advisors LTD., Cormorant Asset Management LP, Goldman Sachs Group Inc., Lord Abbett & CO. LLC, Ensign Peak Advisors Inc, BlackRock Inc., and Federated Hermes Inc..
View insider buying and selling activity for Beam Therapeutics or view top insider-selling stocks.

BEAM stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, MWG Management Limited, Perceptive Advisors LLC, Victory Capital Management Inc., Monashee Investment Management LLC, University of Texas Texas AM Investment Managment Co., Bellevue Group AG, and Morgan Stanley.
View insider buying and selling activity for Beam Therapeutics or or view top insider-buying stocks.

Shares of BEAM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BEAM stock can currently be purchased for approximately $85.00.

Beam Therapeutics has a market capitalization of $5.32 billion and generates $20,000.00 in revenue each year. The company earns $-194,590,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis.

Beam Therapeutics employs 216 workers across the globe.

The official website for Beam Therapeutics is www.beamtx.com.

Beam Therapeutics is headquartered at 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139.

Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-327-8775 or via email at [email protected]